Pruritic Rash in Pregnancy JAMES S
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Obstetrics and Gynecology Pretest® Self-Assessment and Review 10412 Wylen Fm.£.Qxd 6/18/03 10:55 AM Page Ii
10412_Wylen_fm.£.qxd 6/18/03 10:55 AM Page i PRE ® TEST Obstetrics and Gynecology PreTest® Self-Assessment and Review 10412_Wylen_fm.£.qxd 6/18/03 10:55 AM Page ii Notice Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the prod- uct information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs. 10412_Wylen_fm.£.qxd 6/18/03 10:55 AM Page iii PRE ® TEST Obstetrics and Gynecology PreTest® Self-Assessment and Review Tenth Edition Michele Wylen, M.D. -
3628-3641-Pruritus in Selected Dermatoses
Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2016; 20: 3628-3641 Pruritus in selected dermatoses K. OLEK-HRAB 1, M. HRAB 2, J. SZYFTER-HARRIS 1, Z. ADAMSKI 1 1Department of Dermatology, University of Medical Sciences, Poznan, Poland 2Department of Urology, University of Medical Sciences, Poznan, Poland Abstract. – Pruritus is a natural defence mech - logical self-defence mechanism similar to other anism of the body and creates the scratch reflex skin sensations, such as touch, pain, vibration, as a defensive reaction to potentially dangerous cold or heat, enabling the protection of the skin environmental factors. Together with pain, pruritus from external factors. Pruritus is a frequent is a type of superficial sensory experience. Pruri - symptom associated with dermatoses and various tus is a symptom often experienced both in 1 healthy subjects and in those who have symptoms systemic diseases . Acute pruritus often develops of a disease. In dermatology, pruritus is a frequent simultaneously with urticarial symptoms or as an symptom associated with a number of dermatoses acute undesirable reaction to drugs. The treat - and is sometimes an auxiliary factor in the diag - ment of this form of pruritus is much easier. nostic process. Apart from histamine, the most The chronic pruritus that often develops in pa - popular pruritus mediators include tryptase, en - tients with cholestasis, kidney diseases or skin dothelins, substance P, bradykinin, prostaglandins diseases (e.g. atopic dermatitis) is often more dif - and acetylcholine. The group of atopic diseases is 2,3 characterized by the presence of very persistent ficult to treat . Persistent rubbing, scratching or pruritus. -
Guide to Learning in Maternal-Fetal Medicine
GUIDE TO LEARNING IN MATERNAL-FETAL MEDICINE First in Women’s Health The Division of Maternal-Fetal Medicine of The American Board of Obstetrics and Gynecology, Inc. 2915 Vine Street Dallas, TX 75204 Direct questions to: ABOG Fellowship Department 214.871.1619 (Main Line) 214.721.7526 (Fellowship Line) 214.871.1943 (Fax) [email protected] www.abog.org Revised 4/2018 1 TABLE OF CONTENTS I. INTRODUCTION ........................................................................................................................ 3 II. DEFINITION OF A MATERNAL-FETAL MEDICINE SUBSPECIALIST .................................... 3 III. OBJECTIVES ............................................................................................................................ 3 IV. GENERAL CONSIDERATIONS ................................................................................................ 3 V. ENDOCRINOLOGY OF PREGNANCY ..................................................................................... 4 VI. PHYSIOLOGY ........................................................................................................................... 6 VII. BIOCHEMISTRY ........................................................................................................................ 9 VIII. PHARMACOLOGY .................................................................................................................... 9 IX. PATHOLOGY ......................................................................................................................... -
Skin Eruptions Specific to Pregnancy: an Overview
DOI: 10.1111/tog.12051 Review The Obstetrician & Gynaecologist http://onlinetog.org Skin eruptions specific to pregnancy: an overview a, b Ajaya Maharajan MBBS DGO MRCOG, * Christina Aye BMBCh MA Hons MRCOG, c d Ravi Ratnavel DM(Oxon) FRCP(UK), Ekaterina Burova FRCP CMSc (equ. PhD) aConsultant in Obstetrics and Gynaecology, Luton and Dunstable University Hospital, Lewsey Road, Luton, Bedfordshire LU4 0DZ, UK bST5 in Obstetrics and Gynaecology, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK cConsultant Dermatologist, Buckinghamshire Health Care, Mandeville Road, Aylesbury, Buckinghamshire HP21 8AL, UK dConsultant Dermatologist, Skin Cancer Lead for Bedford Hospital, Bedford Hospital NHS Trust, South Wing, Kempston Road, Bedford MK42 9DJ, UK *Correspondence: Ajaya Maharajan. Email: [email protected] Accepted on 31 January 2013 Key content Learning objectives Pregnancy results in various physiological skin changes. To understand the physiological skin changes in pregnancy. As a consequence, some common dermatoses can present more To identify the skin conditions that require appropriate referral. frequently in pregnant women. In addition, there are a number To be able to take a history, to diagnose the skin eruptions unique to of skin eruptions unique to pregnancy. pregnancy, undertake appropriate investigations and first-line The aetiology of physiological skin changes in pregnancy is management, and understand the criteria for referral to a uncertain but is thought to be due to hormonal and physical dermatologist. changes of pregnancy. Keywords: atopic eruption of pregnancy / intrahepatic cholestasis The four dermatoses of pregnancy are: atopic eruption of pregnancy / pemphigoid gestastionis / polymorphic eruption of of pregnancy, pemphigoid gestationis, polymorphic pregnancy / skin eruptions eruption of pregnancy and intrahepatic cholestasis of pregnancy. -
Pruritus: Scratching the Surface
Pruritus: Scratching the surface Iris Ale, MD Director Allergy Unit, University Hospital Professor of Dermatology Republic University, Uruguay Member of the ICDRG ITCH • defined as an “unpleasant sensation of the skin leading to the desire to scratch” -- Samuel Hafenreffer (1660) • The definition offered by the German physician Samuel Hafenreffer in 1660 has yet to be improved upon. • However, it turns out that itch is, indeed, inseparable from the desire to scratch. Savin JA. How should we define itching? J Am Acad Dermatol. 1998;39(2 Pt 1):268-9. Pruritus • “Scratching is one of nature’s sweetest gratifications, and the one nearest to hand….” -- Michel de Montaigne (1553) “…..But repentance follows too annoyingly close at its heels.” The Essays of Montaigne Itch has been ranked, by scientific and artistic observers alike, among the most distressing physical sensations one can experience: In Dante’s Inferno, falsifiers were punished by “the burning rage / of fierce itching that nothing could relieve” Pruritus and body defence • Pruritus fulfils an essential part of the innate defence mechanism of the body. • Next to pain, itch may serve as an alarm system to remove possibly damaging or harming substances from the skin. • Itch, and the accompanying scratch reflex, evolved in order to protect us from such dangers as malaria, yellow fever, and dengue, transmitted by mosquitoes, typhus-bearing lice, plague-bearing fleas • However, chronic itch lost this function. Chronic Pruritus • Chronic pruritus is a common and distressing symptom, that is associated with a variety of skin conditions and systemic diseases • It usually has a dramatic impact on the quality of life of the affected individuals Chronic Pruritus • Despite being the major symptom associated with skin disease, our understanding of the pathogenesis of most types of itch is limited, and current therapies are often inadequate. -
Pemphigoid Gestationis Open Access to Scientific and Medical Research DOI
Journal name: Clinical, Cosmetic and Investigational Dermatology Article Designation: REVIEW Year: 2017 Volume: 10 Clinical, Cosmetic and Investigational Dermatology Dovepress Running head verso: Sävervall et al Running head recto: Pemphigoid gestationis open access to scientific and medical research DOI: http://dx.doi.org/10.2147/CCID.S128144 Open Access Full Text Article REVIEW Pemphigoid gestationis: current perspectives Christine Sävervall1 Abstract: Many skin diseases can occur in pregnant women. However, a few pruritic derma- Freja Lærke Sand1 tological conditions are unique to pregnancy, including pemphigoid gestationis (PG). As PG Simon Francis Thomsen1,2 is associated with severe morbidity for pregnant women and carries fetal risks, it is important for the clinician to quickly recognize this disease and refer it for dermatological evaluation and 1Department of Dermatology, Bispebjerg Hospital, Copenhagen, treatment. Herein, we review the pathogenesis, clinical characteristics, and management of PG. Denmark; 2Department of Biomedical Keywords: pemphigoid gestationis, pregnancy, skin diseases Sciences, University of Copenhagen, Copenhagen, Denmark Introduction Skin changes are common during pregnancy and can be divided into benign physi- For personal use only. ologic skin changes due to normal hormonal/physiological changes,1 alterations in preexisting skin diseases because of immunohormonal changes, and pregnancy-specific dermatoses. Pregnancy-specific dermatoses represent a group of skin diseases that occur only during pregnancy and/or the immediate postpartum period. Severe pruritus represents the leading symptom commonly followed by a more widespread skin rash. Pregnancy-specific dermatoses include: pemphigoid gestationis (PG), polymorphic eruption of pregnancy (PEP), intrahepatic cholestasis of pregnancy (ICP), and atopic eruption of pregnancy (AEP).2 PG or gestational pemphigoid is a rare pregnancy-associated autoimmune skin disorder that is immunologically and clinically similar to the pemphigoid group of autoimmune blistering skin disorders. -
Copyrighted Material
Part 1 General Dermatology GENERAL DERMATOLOGY COPYRIGHTED MATERIAL Handbook of Dermatology: A Practical Manual, Second Edition. Margaret W. Mann and Daniel L. Popkin. © 2020 John Wiley & Sons Ltd. Published 2020 by John Wiley & Sons Ltd. 0004285348.INDD 1 7/31/2019 6:12:02 PM 0004285348.INDD 2 7/31/2019 6:12:02 PM COMMON WORK-UPS, SIGNS, AND MANAGEMENT Dermatologic Differential Algorithm Courtesy of Dr. Neel Patel 1. Is it a rash or growth? AND MANAGEMENT 2. If it is a rash, is it mainly epidermal, dermal, subcutaneous, or a combination? 3. If the rash is epidermal or a combination, try to define the SIGNS, COMMON WORK-UPS, characteristics of the rash. Is it mainly papulosquamous? Papulopustular? Blistering? After defining the characteristics, then think about causes of that type of rash: CITES MVA PITA: Congenital, Infections, Tumor, Endocrinologic, Solar related, Metabolic, Vascular, Allergic, Psychiatric, Latrogenic, Trauma, Autoimmune. When generating the differential, take the history and location of the rash into account. 4. If the rash is dermal or subcutaneous, then think of cells and substances that infiltrate and associated diseases (histiocytes, lymphocytes, mast cells, neutrophils, metastatic tumors, mucin, amyloid, immunoglobulin, etc.). 5. If the lesion is a growth, is it benign or malignant in appearance? Think of cells in the skin and their associated diseases (keratinocytes, fibroblasts, neurons, adipocytes, melanocytes, histiocytes, pericytes, endothelial cells, smooth muscle cells, follicular cells, sebocytes, eccrine -
A Systematic Review of Treatment Options and Clinical Outcomes in Pemphigoid Gestationis
SYSTEMATIC REVIEW published: 20 November 2020 doi: 10.3389/fmed.2020.604945 A Systematic Review of Treatment Options and Clinical Outcomes in Pemphigoid Gestationis Giovanni Genovese 1,2, Federica Derlino 3, Amilcare Cerri 3,4, Chiara Moltrasio 1, Simona Muratori 1, Emilio Berti 1,2 and Angelo Valerio Marzano 1,2* 1 Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy, 2 Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy, 3 Dermatology Unit, ASST Santi Paolo e Carlo, Milan, Italy, 4 Department of Health Sciences, Università degli Studi di Milano, Milan, Italy Background: Treatment regimens for pemphigoid gestationis (PG) are non-standardized, with most evidence derived from individual case reports or small series. Objectives: To systematically review current literature on treatments and clinical outcomes of PG and to establish recommendations on its therapeutic management. Methods: An a priori protocol was designed based on PRISMA guidelines. Edited by: PubMed, Scopus, and Web of Science databases were searched for English-language Savino Sciascia, articles detailing PG treatments and clinical outcomes, published between 1970 and University of Turin, Italy March 2020. Reviewed by: Simone Baldovino, Results: In total, 109 articles including 140 PG patients were analyzed. No randomized University of Turin, Italy controlled trials or robust observational studies detailing PG treatment were found. Simone Ribero, University of Turin, Italy Systemic corticosteroids ± topical corticosteroids and/or antihistamines were the most *Correspondence: frequently prescribed treatment modality (n = 74/137; 54%). Complete remission was Angelo Valerio Marzano achieved by 114/136 (83.8%) patients. Sixty-four patients (45.7%) were given more [email protected] than one treatment modality due to side effects or ineffectiveness. -
Raskauspemfigoidi – Ihotautilääkärin Ja Synnytyslääkärin Yhteinen Haaste
Laura Huilaja, Kaarin Mäkikallio ja Kaisa Tasanen | HARVINAISET SAIRAUDET Raskauspemfigoidi – ihotautilääkärin ja synnytyslääkärin yhteinen haaste raskauksiin ja trofoblastiperäisiin kasvaimiin Raskauspemfigoidi on harvinainen raskausajan liittyviä tapauksia (Semkova ja Black 2009). autoimmuuni-ihosairaus. Istukan tyypin XVII Aikaisemmin raskauspemfigoidista käytettiin kollageenia vastaan muodostuvat vasta-aineet harhaanjohtavaa nimitystä herpes gestationis. aiheuttavat ihon tyvikalvovaurion ja hankalas- ti kutisevan rakkuloivan ihottuman vartalolle Patogeneesi ja raajoihin. Raskauspemfigoidin diagnoosi var- mistetaan erikoissairaanhoidossa ihokudosnäyt- Raskauspemfigoidin patogeneesi on edel- teestä immunofluoresenssitutkimuksella, ja tau- leen tuntematon. MHC-II-luokan (major din aktiivisuuden arvioinnissa voidaan käyttää histocompatibility complex class II) HL- seerumin pemfigoidiantigeeni BP180:n vasta- antigeenien DR3 ja DR4 tai niiden yhdistel- män on osoitettu olevan selvästi yleisempiä aineen määritystä. Systeeminen kortikosteroidi- raskauspemfigoidiin sairastuneilla naisilla hoito on raskauspemfigoidin hoidon kulmakivi, kuin muussa väestössä (Holmes ym. 1983). vaikka lievien oireiden rauhoittamiseen voivat Istukan ja sikiön kudoksissa on äidille vierai- riittää kortikosteroidivoiteet ja antihistamiini. ta, isältä perittyjä kudosantigeeneja, joihin äi- Synnytyksen jälkeen raskauspemfigoidi rauhoit- din immuuni puolustus ei normaalisti reagoi. tuu yleensä itsestään, mutta uusiutuminen seu- Raskauspemfigoidipotilailla istukan trofobas- -
Pretest Obstetrics and Gynecology
Obstetrics and Gynecology PreTestTM Self-Assessment and Review Notice Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the prod- uct information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs. Obstetrics and Gynecology PreTestTM Self-Assessment and Review Twelfth Edition Karen M. Schneider, MD Associate Professor Department of Obstetrics, Gynecology, and Reproductive Sciences University of Texas Houston Medical School Houston, Texas Stephen K. Patrick, MD Residency Program Director Obstetrics and Gynecology The Methodist Health System Dallas Dallas, Texas New York Chicago San Francisco Lisbon London Madrid Mexico City Milan New Delhi San Juan Seoul Singapore Sydney Toronto Copyright © 2009 by The McGraw-Hill Companies, Inc. -
Dr. Dimple Chopra ABSTRACT KEYWORDS
ORIGINAL RESEARCH PAPER VOLUME-6 | ISSUE-8 | AUGUST - 2017 | ISSN No 2277 - 8179 | IF : 4.176 | IC Value : 78.46 INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH MYRIAD OF CUTANEOUS CHANGES IN PREGNANCY: A STUDY IN TERTIARY CARE HOSPITAL IN NORTH INDIA Dermatology Associate Professor, MD Skin and Venereal Diseases, Department of Skin and Venereal Dr. Dimple Chopra Diseases, Government Medical College Patiala. MBBS, Junior Resident, Department of Skin and Venereal Diseases, Government Dr. Aastha Sharma Medical College Patiala. - Corresponding Author Dr. Manjit Kaur Professor, MD Obstetrics and Gynaecology, Department of Obstetrics and Gynaecology, Mohi Government Medical College Patiala. Dr. Rakesh Kumar Associate Professor, MD Skin and Venereal Diseases, Department of Skin and Venereal Bahl Diseases, Government Medical College Patiala. Senior Resident, MD Skin and Venereal Diseases, Department of Skin and Venereal Dr. Karamjit Mohi Diseases, Government Medical College Patiala. ABSTRACT Background: The skin changes in pregnancy can be either physiological, changes in pre-existing skin diseases or development of new pregnancy specific dermatoses. Though cutaneous changes in pregnancy are a common occurrence but very limited data is available on females in North India. Aims: The objective was to study the clinical spectrum of cutaneous manifestations in pregnant females, to differentiate between the physiological and pathological skin changes and categorize these as dermatoses specific and non-specific to pregnancy. Methods: In this cross-sectional observational study 200 patients presenting with cutaneous complaints irrespective of their parity and gestational age were included. Thorough examination and relevant investigations were done wherever necessary. Results: Pigmentary changes were the most common physiological change observed. Linea nigra in 129 patients (64.5%), darkening of areolae in 113 (56.5%) cases and melasma, the most common physiological change of cosmetic concern was seen in 109(54.5%) cases. -
Benefits and Risks of Igg Transplacental Transfer
diagnostics Review Benefits and Risks of IgG Transplacental Transfer 1,2, 1, 1,2, 1,2 Anca Marina Ciobanu y, Andreea Elena Dumitru y, Nicolae Gica y , Radu Botezatu , Gheorghe Peltecu 1,2 and Anca Maria Panaitescu 1,2,* 1 Filantropia Clinical Hospital, Bucharest 11171, Romania; [email protected] (A.M.C.); [email protected] (A.E.D.); [email protected] (N.G.); [email protected] (R.B.); [email protected] (G.P.) 2 Carol Davila University of Medicine and Pharmacy, Bucharest 020021, Romania * Correspondence: [email protected]; Tel.: +40-213-188-937 These authors are equally contributed to this work. y Received: 1 July 2020; Accepted: 10 August 2020; Published: 12 August 2020 Abstract: Maternal passage of immunoglobulin G (IgG) is an important passive mechanism for protecting the infant while the neonatal immune system is still immature and ineffective. IgG is the only antibody class capable of crossing the histological layers of the placenta by attaching to the neonatal Fc receptor expressed at the level of syncytiotrophoblasts, and it offers protection against neonatal infectious pathogens. In pregnant women with autoimmune or alloimmune disorders, or in those requiring certain types of biological therapy, transplacental passage of abnormal antibodies may cause fetal or neonatal harm. In this review, we will discuss the physiological mechanisms and benefits of transplacental transfer of maternal antibodies as well as pathological maternal situations where this system is hijacked, potentially leading to adverse neonatal outcomes. Keywords: immunoglobulin G; pregnancy; vaccine; transplacental transfer; autoimmune disorders; alloimmune disorders 1. Introduction Immunological adaptative changes occurring during pregnancy allow maternal tolerance towards the fetus and placenta, which practically constitute semi-allografts as 50% of their antigens have a paternal provenience [1].